“Considering that less than two weeks ago CHIA’s annual report found that prescription drugs are not a leading driver of healthcare costs in Massachusetts, it’s astonishing that the Governor is again trying to push his tired proposal on prescription drug price controls. In practice, this policy would do nothing to reduce costs for patients but would inhibit the biopharmaceutical industry’s ability to develop innovative, life-changing treatments and cures – like the COVID-19 vaccines, which Massachusetts residents are currently benefitting from. It bears repeating that this policy is unnecessary and ignores the numerous, existing tools the Massachusetts state government can use to reduce prescription drug spending. We look forward to working with legislative leadership in the House and Senate to identify common sense solutions that help patients struggling with growing out-of-pocket costs and high deductibles.”
– Zachary Stanley, Executive Vice President, MassBio